Abstract
The use of immunotherapy in the treatment of non-Hodgkin lymphomas has improved response rates and survival in this population. With widespread rituximab use and longer-term follow-up of patients receiving rituximab, infectious complications are increasing. These complications are of great concern in the AIDS-related lymphoma population. We review the data on activity and infectious toxicity of rituximab to date and as it pertains to the treatment of AIDSrelated non-Hodgkin lymphoma and Multicentric Castlemans disease.
Keywords: AIDS, AIDS related Lymphoma, HAART, HIV, JC Polyoma virus associated progressive multifocal leukoencyphalopathy, Multicentric castleman's disease, non-hogdkin's lymphoma, rituximab, lymphoma, hepatitis B, hepatitis C, dose adjusted EPOCH, CHOP, CODOX-IVAC, magrath regimen, kaposi sarcoma, bortezomib
Current Drug Delivery
Title: Clinical Use of Rituximab in Patients with HIV Related Lymphoma and Multicentric Castlemans Disease
Volume: 9 Issue: 1
Author(s): Erin Reid, Ajay Nooka, Jawaunna Blackmon and Mary Jo Lechowicz
Affiliation:
Keywords: AIDS, AIDS related Lymphoma, HAART, HIV, JC Polyoma virus associated progressive multifocal leukoencyphalopathy, Multicentric castleman's disease, non-hogdkin's lymphoma, rituximab, lymphoma, hepatitis B, hepatitis C, dose adjusted EPOCH, CHOP, CODOX-IVAC, magrath regimen, kaposi sarcoma, bortezomib
Abstract: The use of immunotherapy in the treatment of non-Hodgkin lymphomas has improved response rates and survival in this population. With widespread rituximab use and longer-term follow-up of patients receiving rituximab, infectious complications are increasing. These complications are of great concern in the AIDS-related lymphoma population. We review the data on activity and infectious toxicity of rituximab to date and as it pertains to the treatment of AIDSrelated non-Hodgkin lymphoma and Multicentric Castlemans disease.
Export Options
About this article
Cite this article as:
Reid Erin, Nooka Ajay, Blackmon Jawaunna and Jo Lechowicz Mary, Clinical Use of Rituximab in Patients with HIV Related Lymphoma and Multicentric Castlemans Disease, Current Drug Delivery 2012; 9 (1) . https://dx.doi.org/10.2174/156720112798376005
DOI https://dx.doi.org/10.2174/156720112798376005 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advancements in Robotic and AI-based Drug Discovery and Delivery for Neurological Disorders
Neurological disorders, including Alzheimer's disease, Parkinson's disease, epilepsy, and brain tumors, pose significant challenges in drug delivery due to the blood-brain barrier's intricate structure and the complexity of neuronal networks. Traditional drug delivery methods often fall short in reaching therapeutic concentrations within the central nervous system, limiting treatment efficacy and ...read more
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bioluminescence Imaging in Rodents: When Light Illuminates Cancer Research
Current Molecular Imaging (Discontinued) Noxa: Role in Cancer Pathogenesis and Treatment
Current Cancer Drug Targets Carotenoids as Modulators of Intracellular Signaling Pathways
Current Signal Transduction Therapy Inhibition of Multidrug Resistance of Cancer Cells by Natural Diterpenes, Triterpenes and Carotenoids
Current Pharmaceutical Design Editorial (Thematic Issue: The Urgent Need to Reform the Present System of Medicines’ Regulation)
Reviews on Recent Clinical Trials p53: An Attractive Therapeutic Target for Cancer
Current Medicinal Chemistry Targeted Cancer Immunotherapy Using Ligands of the Tumor Necrosis Factor Super-Family
Current Drug Targets Small-Animal Molecular Imaging for Preclinical Cancer Research: μPET and μSPECT
Current Radiopharmaceuticals Pyrimidine Nucleosides in Molecular PET Imaging of Tumor Proliferation
Current Medicinal Chemistry Systemic and Biophase Bioavailability and Pharmacokinetics of Nanoparticulate Drug Delivery Systems
Current Drug Delivery Theranostic Systems and Strategies for Monitoring Nanomedicine-Mediated Drug Targeting
Current Pharmaceutical Biotechnology The Herpesvirus Encoded dUTPase as a Potential Chemotherapeutic Target
Current Protein & Peptide Science The Effect of Casein Kinase 2 Inhibition on three Leukemic Cell Lines
Current Drug Therapy Polyethylenimine-based Formulations for Delivery of Oligonucleotides
Current Medicinal Chemistry Discovery of New Aminosubstituted Pyrrolopyrimidines with Antiproliferative Activity Against Breast Cancer Cells and Investigation of their Effect Towards the PI3Kα Enzyme
Anti-Cancer Agents in Medicinal Chemistry 2-Arylbenzimidazoles as Antiviral and Antiproliferative Agents-Part 1
Medicinal Chemistry Pyridine and Pyrimidine Derivatives as Privileged Scaffolds in Biologically Active Agents
Current Medicinal Chemistry Molecular Pathways Linking Inflammation and Cancer
Current Molecular Medicine Mechanisms of Resistance Against Cancer Therapeutic Drugs
Current Pharmaceutical Biotechnology In Vivo Imaging of Apoptosis in Cancer: Potentials and Drawbacks of Molecular Probes
Current Molecular Imaging (Discontinued)